Purpose: The summary presented herein represents Part I of the two-part series dedicated to
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and …

Background Currently, there is no universally accepted prognostic classification for patients
(pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen …

Bone metastatic prostate cancer (BM-PCa) significantly reduces overall patient survival and
is currently incurable. Current standard immunotherapy showed promising results for PCa …

Objective Cancer of the pancreas is a life-threatening condition and has a high distant
metastasis (DM) rate of over 50% at diagnosis. Therefore, this study aimed to determine …

Background The incidence of prostate cancer (PCa) has continued to increase since the US
Preventive Services Task Force (USPSTF) recommendations against prostate-specific …

Background Genetic profiling of patients with prostate cancer could potentially identify
mutations prone to castration-resistant prostate cancer (CRPC). Here, we aimed to identify …

Prostate cancer (PCa) is the most frequent malignancy in older men with a high propensity
for bone metastases. Characteristically, PCa causes osteosclerotic lesions as a result of …

Objectives No uniformity exists in the definition of metastatic burden in metastatic hormone-
naive prostate cancer (mHNPC) across clinical trials making their comparison challenging …

Background Five-year survival in patients with localized prostate cancer (PCa) is nearly
100%, but metastatic disease still remains incurable. Clinical management of metastatic …

Background More than 80% of advanced prostate cancer (PCa) cases have bone
metastasis, with a 5-year survival rate of 25%. Previously, we reported that GRT, a …